Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Sana Biotechnology
Persicabtagene lemgedleucel is an allogeneic CAR-T cell therapy made from human T-lymphocytes transduced with a chimeric antigen receptor specific for CD19, with MHC class I and II expression disrupted and CD47 expressed to reduce immune rejection of the donor cells. It is studied in non-Hodgkin lymphoma and chronic lymphocytic leukemia, where it binds CD19-expressing tumor cells and mediates their killing.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05878184 | Phase 1 | Non Hodgkin Lymphoma | Active not recruiting | SANA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the SANA page.
See SANA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SANA catalysts and pipeline →